Myelofibrosis Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, Menarini Group, Telios Pharma, Novartis Pharmaceutical

DelveInsight's "Myelofibrosis - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Myelofibrosis market share of the individual therapies, current and forecasted Myelofibrosis market size from 2020 to 2034 segmented by seven major markets. The report also offers current Myelofibrosis therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Myelofibrosis market.
Download our report @ https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights of the myelofibrosis market report:
In 2023, the myelofibrosis market in the US led the 7MM with a market size of approximately USD 1,400 million, and this is projected to grow by 2034. Within the 7MM, JAKAFI/JAKAVI (ruxolitinib) dominated the market with a valuation of about USD 1,500 million. JAK inhibitors have become central to myelofibrosis treatment, offering significant benefits in spleen reduction, symptom relief, and overall quality of life, potentially improving patient longevity in advanced stages of the disease.
Key myelofibrosis companies working in the myelofibrosis market are Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, Menarini Group, Telios Pharma, Novartis Pharmaceuticals, NS Pharma, Karyopharm Therapeutics, Incyte Corporation, Celgene/Bristol Myers Squibb, MorphoSys, Imago BioSciences, Roche, and others.
Emerging therapies are exploring various mechanisms beyond JAK inhibitors, including imetelstat (a telomerase inhibitor), navitoclax (a BCL-XL/BCL-2 inhibitor), navtemadlin (an MDM2 protein inhibitor), and pelabresib (a BET inhibitor). These new treatments aim to address patient needs and provide alternative options.
AbbVie anticipates results from the Phase III TRANSFORM-2 trial of navitoclax for relapsed/refractory myelofibrosis in 2024. Additionally, Disc Medicine plans to present updated Phase Ib/II data for DISC-0974, focusing on anemia in myelofibrosis patients, in the first half of 2024. In January 2024, Geron Corporation's Phase I IMproveMF study, which evaluates imetelstat in combination with ruxolitinib for intermediate-2 or high-risk myelofibrosis, advanced to the third dose level following a positive review by the study's independent safety evaluation team (SET).

Myelofibrosis Overview
Myelofibrosis is a rare blood cancer marked by the accumulation of scar tissue, known as "fibrosis," in the bone marrow, which impairs its ability to produce healthy blood cells. It falls under the category of myeloproliferative neoplasms (MPNs), where bone marrow cells produce abnormal blood cells. Primary myelofibrosis occurs independently, whereas secondary myelofibrosis arises from another MPN, such as polycythemia vera (PV) or essential thrombocythemia (ET), and is also known as post-PV or post-ET myelofibrosis.

The disease often progresses slowly and may be detected incidentally through routine blood tests due to its initial lack of symptoms. As fibrosis builds up in the bone marrow, it fails to generate sufficient normal blood cells, leading to various signs and symptoms. Key genetic mutations associated with myelofibrosis include the Janus kinase 2 (JAK2) mutation, as well as less common mutations such as CALR and MPL. Some individuals may not have identifiable gene mutations.

Common clinical manifestations of myelofibrosis include anemia, hepatosplenomegaly (enlarged liver and spleen), and systemic symptoms like fatigue, night sweats, low-grade fever, progressive cachexia (muscle loss), bone pain, splenic infarcts, itching, extramedullary hematopoiesis (EMH outside the bone marrow), thrombosis, and bleeding.
Myelofibrosis is diagnosed through a combination of tests, including blood tests, bone marrow analysis, molecular testing, and mutation-enhanced morphologic evaluation. To confirm the diagnosis, bone marrow testing involves two procedures: a bone marrow aspiration to collect a liquid sample and a bone marrow biopsy to obtain a solid sample of bone filled with marrow. Molecular tests assess genetic, chromosomal, and protein abnormalities in cancer cells to aid in diagnosis and treatment planning.

Allogeneic stem cell transplantation is currently the only potential cure for myelofibrosis, but it is often not suitable for older patients or those with other health issues. Consequently, treatment generally focuses on managing symptoms, improving quality of life, and extending survival. Approved treatments include JAKAFI/JAKAVI (ruxolitinib), INREBIC (fedratinib), VONJO (pacritinib), and OJJAARA/OMJJARA (momelotinib). For low-risk patients, options may include ruxolitinib, Interferon alfa, and hydroxyurea, while intermediate and high-risk patients may be treated with pacritinib, ruxolitinib, fedratinib, or potentially stem cell transplantation.
To know more about myelofibrosis, causes. Signs and symptoms, diagnosis, treatment options, visit: https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Myelofibrosis Epidemiological Insights
In 2023, the total number of prevalent myelofibrosis cases across the 7MM was approximately 56,000, with expectations for this number to rise throughout the study period (2020-2034). Among the EU4 countries and the UK, Germany reported the highest number of diagnosed cases, followed by Spain, while the UK had the lowest incidence of myelofibrosis in 2023.
Myelofibrosis cases are categorized based on risk levels: low, intermediate-1, intermediate-2, and high. In the US, the high-risk category had the largest patient population in 2023. Myelofibrosis is also divided into primary and secondary forms, with primary myelofibrosis representing 75% of all cases in the US that year.
Age-wise, cases in the US are divided into three groups: under 40 years, 40-69 years, and 70 years and older. The 70 years and older group had the highest number of patients, approximately 12,000 in 2023. Additionally, JAK2 mutations were present in about 60% of myelofibrosis cases in the US.
Myelofibrosis Market
Myelofibrosis has limited treatment options, with allogeneic hematopoietic cell transplantation being the only curative therapy, though only a small number of patients receive it. The disease presents a wide range of symptoms, including anemia, splenomegaly, constitutional symptoms, bone pain, and bleeding. Effective treatment often requires managing these multiple symptoms.

For many years, JAKAFI (ruxolitinib) was the only approved medication for intermediate- or high-risk myelofibrosis. This changed in August 2019 with the approval of INREBIC (fedratinib), a second JAK inhibitor. In February 2022, VONJO (pacritinib) was approved for adults with intermediate or high-risk primary or secondary myelofibrosis who have a platelet count below 50 × 10^9/L and for whom other JAK inhibitors are not suitable. Most recently, in September 2023, the US FDA approved OJJAARA (momelotinib). This is the first agent approved to address anemia, constitutional symptoms, and splenomegaly in both newly diagnosed and previously treated myelofibrosis patients.

Ongoing research is exploring combination therapies to reduce myelofibrosis-related symptoms and address dose-limiting cytopenias, particularly in patients who cannot tolerate or whose disease is resistant to JAK inhibitor monotherapy. Recent Phase III trials have shown that combining other drugs with ruxolitinib in JAK inhibitor-naive patients significantly improves outcomes compared to ruxolitinib alone.
Myelofibrosis market insights:
According to DelveInsight's estimates, several drugs are expected to significantly impact the myelofibrosis market over the forecast period, including Navtemadlin (KRT-232), Selinexor, Imetelstat, Navitoclax, Luspatercept, and Pelabresib, among others.
In 2023, the total myelofibrosis market size across the 7MM was approximately USD 1,800 million and is anticipated to grow during the forecast period from 2024 to 2034. Among the EU4 countries and the UK, Germany had the largest market size in 2023, while the UK had the smallest.
JAKAFI (ruxolitinib) is projected to be the highest revenue-generating therapy in the 7MM by 2034.

Promising Therapies in the Myelofibrosis Pipeline
JAKAFI (Ruxolitinib)
INREBIC (Fedratinib)
VONJO (Pacritinib)
Momelotinib
Navitoclax (ABT-263)
Parsaclisib (INCB050465)
REBLOZYL (Luspatercept/ACE-536)
Pelabresib
And others
Discover more about Myelofibrosis therapies in the pipeline @ https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Myelofibrosis Market
Incyte
Novartis
Impact Biomedicines
Celgene
CTI BioPharma
Sierra Oncology
AbbVie
Bristol Myers Squibb
MorphoSys
And others
To understand key companies related to the Myelofibrosis Market, get a snapshot of the Myelofibrosis Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Myelofibrosis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Myelofibrosis Companies: Incyte, Novartis, Impact Biomedicines, Celgene, CTI BioPharma, Sierra Oncology, AbbVie, Bristol Myers Squibb, MorphoSys, and others
Key Myelofibrosis Pipeline Therapies: JAKAFI (Ruxolitinib), INREBIC (Fedratinib), VONJO (Pacritinib), Momelotinib, Navitoclax (ABT-263), Parsaclisib (INCB050465), REBLOZYL (Luspatercept/ACE-536), Pelabresib, and others
Therapeutic Assessment: Myelofibrosis current marketed and emerging therapies
Myelofibrosis Market Dynamics: Myelofibrosis market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Myelofibrosis Market Access and Reimbursement
Table of Contents
1. Myelofibrosis Market Key Insights
2. Myelofibrosis Market Report Introduction
3. Myelofibrosis Market Overview at a Glance
4. Myelofibrosis Market Executive Summary
5. Disease Background and Overview
6. Myelofibrosis Treatment and Management
7. Myelofibrosis Epidemiology and Patient Population
8. Patient Journey
9. Myelofibrosis Emerging Drugs
10. 7MM Myelofibrosis Market Analysis
11. Myelofibrosis Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Myelofibrosis Market Drivers
15. Myelofibrosis Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.